Hypertension in CKD Market, By Drug Class (Diuretics, RAS Blockade, ß-Blockers, Calcium Channel Blockers, Others (a-Blockers, Vasodilators, Proteinuria, etc.) ), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geogr

Hypertension in CKD Market, By Drug Class (Diuretics, RAS Blockade, β-Blockers, Calcium Channel Blockers, Others (α-Blockers, Vasodilators, Proteinuria, etc.) ), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Hypertension in CKD Market, By Drug Class (Diuretics, RAS Blockade, β-Blockers, Calcium Channel Blockers, Others (α-Blockers, Vasodilators, Proteinuria, etc.) ), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Chronic kidney disease (CKD) is a common cause of and a result of uncontrolled hypertension. The interaction between hypertension and CKD is complex and increases the risk of adverse cardiovascular and cerebrovascular outcomes. The pathophysiology of hypertension in CKD is complex, with multiple factors contributing, including decreased nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nervous system overactivity, hormone activation, including the renin-angiotensin-aldosterone system, and endothelial dysfunction. Hypertension in Chronic Kidney Disease (CKD) patients is treated with drug classes such as diuretics, RAS blockade, β - blockers, calcium channel blockers. According to the Centre for Disease Control and Prevention, in 2022 more than 1 in 7 U.S. adults–about 35.5 Mn people, or 14% of the U.S. population are estimated to have CKD. Growing prevalence of CKD is increasing the demand for new drugs and medicines and Key players are actively involved in increasing their research and developmental activities and clinical trials, which are expected to bolster thw growth of Hypertension in CKD Market

Market Dynamics

The Key players are indulged in collaborating in order to conduct clinical trials for different diseases. For instance, on June 12, 2023, Novartis AG, a global pharmaceutical company, announced an agreement to acquire Chinook Therapeutics, a clinical-stage biotechnology company developing precision medicines for kidney diseases with an innovative medicine strategy and renal pipeline. Moreover, increasing product launches by key players is expected to drive growth of the market over the forecast period. For instance, on January 24, 2023, Boehringer Ingelheim International GmbH, a Germany-based global pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for phase III trial for Jardiance, which is being investigated to reduce the risk of kidney disease progression or cardiovascular death in adults with CKD.

Key features of the study:

• This report provides an in-depth analysis of the global hypertension in CKD market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global hypertension in CKD market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG., C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd., KBP Biosciences Holdings Limited, Ardelyx, Reata Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, Pfizer Inc., Bayer Pharmaceuticals, Inc, GSK plc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global hypertension in CKD market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypertension in CKD market

Global Hypertension in CKD Market Detailed Segmentation:

• By Drug Class:
• Diuretics
• RAS Blockade
• β-Blockers
• Calcium Channel Blockers
• Others (α-Blockers, Vasodilators, Proteinuria, etc.)
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Company Profiles
• Sanofi S.A
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• AstraZeneca Plc
• Novartis International AG
• H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd.
• KBP Biosciences Holdings Limited
• Ardelyx
• Reata Pharmaceuticals, Inc.
• Kissei Pharmaceutical Co., Ltd
• Pfizer Inc.
• Bayer Pharmaceuticals, Inc
• GSK plc.